DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

Phase 3

Terminated

Conditions: Osteogenesis Imperfecta (OI)

Interventions: Drug: Alternative osteoporosis medications
Drug: Denosumab

First Posted Date: 2018-08-20

Last Posted Date: 2022-12-20

Lead Sponsor: Amgen

Target Recruit Count: 75

Registration Number: NCT03638128

Locations: 🇬🇧
Birmingham Childrens Hospital, Birmingham, United Kingdom
🇦🇺
Perth Childrens Hospital, Nedlands, Western Australia, Australia
🇨🇦
Shriners Hospital for Children, Montreal, Quebec, Canada

and more 19 locations

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

Phase 4

Completed

Conditions: Gout

Interventions: Biological: Pegloticase
Drug: Methotrexate (MTX)
Drug: Standard Gout Flare Prophylaxis
Drug: Infusion Reaction (IR) Prophylaxis
Dietary Supplement: Folic Acid

First Posted Date: 2018-08-17

Last Posted Date: 2024-06-26

Lead Sponsor: Amgen

Target Recruit Count: 14

Registration Number: NCT03635957

Locations: 🇺🇸
Avail Clinical Research, DeLand, Florida, United States
🇺🇸
Arthritis Northwest PLLC, Spokane, Washington, United States
🇺🇸
Western Washington Arthritis Clinic, Bothell, Washington, United States

and more 3 locations

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Phase 3

Recruiting

Conditions: Secondary Hyperparathyroidism
Chronic Kidney Disease

Interventions: Drug: Etelcalcetide

First Posted Date: 2018-08-16

Last Posted Date: 2025-05-08

Lead Sponsor: Amgen

Target Recruit Count: 56

Registration Number: NCT03633708

Locations: 🇹🇷
Firat Universitesi Hastanesi, Elazig, Turkey
🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Childrens Hospital Colorado, Aurora, Colorado, United States

and more 40 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

Phase 1

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: Placebo
Drug: AMG 890

First Posted Date: 2018-08-13

Last Posted Date: 2024-11-15

Lead Sponsor: Amgen

Target Recruit Count: 79

Registration Number: NCT03626662

Locations: 🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸
New York University, New York, New York, United States
🇺🇸
QPS Miami Research Associates, South Miami, Florida, United States

and more 6 locations

A Phase1 Study of VIB9600

Phase 1

Terminated

Conditions: Safety Issues

Interventions: Drug: Placebos
Biological: VIB9600

First Posted Date: 2018-08-08

Last Posted Date: 2024-12-13

Lead Sponsor: Amgen

Target Recruit Count: 24

Registration Number: NCT03621605

Locations: 🇺🇸
CTI Clinical Trial & Consulting Clinical Research Center, Cincinnati, Ohio, United States

An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients

Phase 3

Withdrawn

Conditions: Heart Transplantation, Elevated Resting Heart Rate

Interventions: Drug: Ivabradine

First Posted Date: 2018-08-07

Last Posted Date: 2018-11-19

Lead Sponsor: Amgen

Registration Number: NCT03619187

Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)

Completed

Conditions: Arthritis, Psoriatic

Interventions: Drug: Apremilast

First Posted Date: 2018-08-01

Last Posted Date: 2024-06-05

Lead Sponsor: Amgen

Target Recruit Count: 102

Registration Number: NCT03608657

Locations: 🇨🇦
Toronto Western Hospital, University Health Network, Toronto, Canada
🇨🇦
The Waterside Clinic, Barrie, Canada
🇨🇦
Adachi Medicine Professional Corporation, Hamilton, Canada

and more 16 locations

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1

Active, not recruiting

Conditions: KRAS p.G12C Mutant Advanced Solid Tumors

Interventions: Drug: sotorasib
Drug: Anti PD-1/L1
Drug: Midazolam

First Posted Date: 2018-07-26

Last Posted Date: 2025-02-07

Lead Sponsor: Amgen

Target Recruit Count: 713

Registration Number: NCT03600883

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Gibbs Cancer Center and Research Institute - Spartanburg, Spartanburg, South Carolina, United States

and more 130 locations

Imaging of Coronary Plaques in Participants Treated With Evolocumab

Phase 3

Completed

Conditions: Coronary Artery Disease (CAD)

Interventions: Drug: Placebo
Drug: Evolocumab
Drug: Statin therapy

First Posted Date: 2018-06-27

Last Posted Date: 2022-05-03

Lead Sponsor: Amgen

Target Recruit Count: 164

Registration Number: NCT03570697

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇭🇺
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary

and more 30 locations

A Study of CCX140-B in Subjects With FSGS

Phase 2

Completed

Conditions: Glomerulosclerosis
FSGS
Focal Segmental Glomerulosclerosis

Interventions: Other: Placebo
Drug: CCX140-B

First Posted Date: 2018-05-25

Last Posted Date: 2025-03-13

Lead Sponsor: Amgen

Target Recruit Count: 46

Registration Number: NCT03536754

Locations: 🇺🇸
Los Angeles Biomedical Research Institute, Torrance, California, United States
🇨🇦
Sunnybrook Health Sciences Centre (Odette Cancer Center), Toronto, Ontario, Canada
🇺🇸
MGH, Boston, Massachusetts, United States

and more 34 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy